Skip to content

Trial Summary

IGNITE a phase II signal seeking trial of adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with cyclin E1 (CCNE 1) over expression with and without gene amplification.

Acronym:

IGNITE

ACTRN/NCT /ethics:

ACTRN12619001185156

Scientific title:

Adavosertib targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC) | IGNITE

Sponsor / Cooperative group:

ANZGOG

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2020-03-01
Anticipated End Date2023-03-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusNot Yet Recruiting